Axim-Sapphire_Logo_-04 (1).png
AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis
02 août 2017 09h00 HE | AXIM Biotechnologies, Inc
NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...